Product Description
Cogent Biosciences is developing ACTR-087 as a treatment for multiple myeloma and b-cell lymphoma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03266692, https://clinicaltrials.gov/ct2/show/NCT02776813)
Mechanisms of Action: 4-1BB Inhibitor,CD3 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cogent Biosciences
Company Location: CAMBRIDGE MA 02140
Company CEO: Andrew Robbins
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Multiple Myeloma|Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| UT-201501 | P1 |
Completed |
Lymphoma, B-Cell |
2020-02-12 |
50% |
2020-11-10 |
Primary Endpoints|Treatments |
| ATTCK-17-01 | P1 |
Terminated |
Multiple Myeloma |
2019-10-01 |
31% |
2020-11-10 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/07/2019 |
News Article |
Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting |
|
11/04/2019 |
News Article |
Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers |
|
10/02/2019 |
News Article |
Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting |
|
09/05/2019 |
News Article |
Unum Therapeutics to Present at Upcoming Industry Conferences in September |